Benzinga | Sep 1, 2020 05:46AM EDT

Wedbush Downgrades Aimmune Therapeutics to Neutral, Lowers Price Target to $34.5

Wedbush analyst Liana Moussatos downgrades Aimmune Therapeutics (NASDAQ:AIMT) from Outperform to Neutral and lowers the price target from $66 to $34.5.